Follow a structured botanical antimicrobial protocol with biofilm disruption

A structured 28-day botanical antimicrobial ramp-up protocol combined with biofilm disruption, designed for suspected chronic Eurasian borreliosis (B. garinii and/or B. afzelii). Based on a tested protocol approach using herbs with demonstrated in vitro activity against Borrelia species, including B. garinii specifically.

This protocol is not a substitute for medical diagnosis or treatment. Consult a healthcare provider before starting. Order baseline high-sensitivity CRP before Day 1 and start a daily symptoms journal (pain 1–10, energy 1–10, neurological symptoms, sleep quality).

Research Basis

The herbs in this protocol were selected based on published laboratory research:

Feng et al. (2020), Frontiers in Medicine — tested 12 botanical medicines against both growing and dormant (persister) forms of B. burgdorferi. Cryptolepis sanguinolenta was the only agent — including antibiotics doxycycline and cefuroxime — to achieve complete eradication of stationary-phase Borrelia with no regrowth in subculture. Japanese knotweed, black walnut, cat's claw, Artemisia annua, and Chinese skullcap also showed significant activity against persisters.
Goc et al. (2015, 2016), Journal of Applied Microbiology / International Journal of Biological Sciences — one of the few studies testing compounds against B. garinii directly (the neurotropic Eurasian species). Baicalein from Chinese skullcap was effective against all three morphological forms (spirochetes, round bodies, and biofilm) of both B. burgdorferi and B. garinii, reducing biofilms by 30–60%.
Theophilus et al. (2015), European Journal of Microbiology and Immunology — whole-leaf Stevia rebaudiana extract reduced Borrelia biofilm by 40% on plastic and 34% on collagen surfaces, outperforming individual antibiotics and a triple-antibiotic combination. Only whole-leaf extract was effective — purified stevioside sweeteners were not tested.
Feng et al. (2017), Frontiers in Medicine — garlic essential oil sterilized stationary-phase Borrelia cultures at 0.05% concentration, the most effective of 34 essential oils tested.

Protocol Structure

Three tracks are introduced in sequence to minimize Herxheimer reactions and isolate tolerance issues:

Biofilm disruptors (Days 1–3 alone, then ongoing) — weaken the protective biofilm matrix before antimicrobials are introduced
Tier 1 antimicrobial herbs (Days 4–16, staggered) — four herbs introduced one at a time, each ramping from half to full dose over 3 days
Tier 2 antimicrobial herbs (Day 21+) — one or two additional herbs chosen based on suspected co-infections or clinical priorities

flowchart TD
    A[Day 1 - Biofilm disruptors only] --&gt; B[Day 4 - Add Cryptolepis half dose]
    B --&gt; C[Day 7 - Cryptolepis full, add Black walnut half]
    C --&gt; D[Day 10 - Black walnut full, Biofilm full, add Knotweed half]
    D --&gt; E[Day 13 - Knotweed full, add Cats claw half]
    E --&gt; F[Day 16 - All Tier 1 herbs at full dose]
    F --&gt; G[Day 21 - Add Tier 2 herb half dose]
    G --&gt; H[Day 28 - Full protocol established]
    H --&gt; I[Week 8 - CRP checkpoint]
    I --&gt; J[Week 12 - CRP decision point]
    J --&gt; K[Month 4 to 9 - Maintenance]
    K --&gt; L[Month 6 to 9 - Begin tapering]

Days 1–3: Biofilm Disruptors Only

Take on an empty stomach each morning. No antimicrobial herbs yet — give the disruptors a head start weakening the biofilm matrix.

NAC 600 mg
Serrapeptase 60,000 SPU (enteric-coated)
Nattokinase 1,000 FU
Stevia whole-leaf extract: 1 dropper in water
Drink 3+ liters water daily throughout the entire protocol

Days 4–6: First Herb — Cryptolepis

Continue biofilm disruptors at half dose. Add:

Cryptolepis tincture: 1/2 tsp (2.5 mL) with breakfast + 1/2 tsp with dinner

Cryptolepis leads because it has the strongest single-agent evidence — the only compound to achieve complete eradication of stationary-phase Borrelia in the Feng et al. study. Monitor for Herxheimer reaction (temporary worsening from bacterial die-off). This is expected and indicates activity.

Days 7–9: Cryptolepis Full + Black Walnut

Cryptolepis: increase to 1 tsp (5 mL) 3x/day with meals
Black walnut green hull tincture: 1/2 tsp 2x/day with meals

Days 10–12: Black Walnut Full + Biofilm Full + Japanese Knotweed

Black walnut: increase to 1 tsp 3x/day with meals
Biofilm disruptors to full dose: NAC 600 mg 2x/day, serrapeptase 120,000 SPU morning, nattokinase 2,000 FU morning, stevia 1–2 droppers 2x/day
Japanese knotweed: 250 mg 2x/day with meals

Days 13–15: Knotweed Full + Cat's Claw

Japanese knotweed: increase to 500 mg 3x/day with meals
Cat's claw: 250 mg 2x/day with meals

Days 16–20: All Tier 1 at Full Dose

Cat's claw: increase to 500 mg 3x/day
All four Tier 1 herbs now at full dose. Settle into the routine.

Days 21–28: Add Tier 2 Herb

Choose one based on clinical picture:

Chinese skullcap (baicalein) 500 mg — tested directly against B. garinii (Goc et al. 2015); the strongest Eurasian-species-specific evidence; also inhibits COX-2/NF-kB inflammation
Artemisia annua 500 mg — if Babesia co-infection suspected (night sweats, air hunger, temperature dysregulation); also showed persister activity in Feng et al.
Allicin (stabilized garlic) 450 mg — disrupts biofilm quorum sensing; related garlic compounds showed sterilizing activity in Feng et al. 2017

Start at half dose (1x/day) on Day 21, increase to full dose (2–3x/day) by Day 24. A second Tier 2 herb may be added at Day 27.

Full Daily Schedule (Day 28 Onward)

Time	Take
6:30 AM empty stomach	NAC 600 mg + serrapeptase 120K SPU + nattokinase 2K FU
7:00 AM breakfast	Cryptolepis 1 tsp + black walnut 1 tsp + knotweed 500 mg + cat's claw 500 mg + Tier 2 herb + stevia 1-2 droppers
12:00 PM lunch	Cryptolepis 1 tsp + black walnut 1 tsp + knotweed 500 mg + cat's claw 500 mg + Tier 2 herb
6:00 PM dinner	Cryptolepis 1 tsp + black walnut 1 tsp + knotweed 500 mg + cat's claw 500 mg + stevia 1-2 droppers
9:00 PM	NAC 600 mg

Monitoring Checkpoints

Week 8: Test CRP and compare to baseline. Review symptoms journal.

CRP dropped more than 30%: continue protocol
CRP dropped 10-30%: continue, retest at Week 12
No change: continue to Week 12 before deciding

Week 12: Test CRP again. This is the key decision point.

CRP dropping + symptoms improving: continue 3-6 more months
CRP stable + mixed symptoms: continue 3 months, consider swapping Tier 2 herbs
No CRP change + no improvement: protocol is not working — seek medical evaluation
CRP rising + symptoms worse: stop all antimicrobials immediately and see a doctor

Tapering (After 6-9 Months of Response)

Drop herbs one at a time with 2-week observation gaps: Tier 2 herbs first, then cat's claw, black walnut, Japanese knotweed, and cryptolepis last (strongest standalone evidence). If symptoms return after dropping a herb, resume it for 2 more months before trying again. Continue biofilm disruptors for 4 weeks after the last herb is stopped. Test CRP at 2 weeks and 4 weeks after full stop.

Herxheimer Reaction Management

Worsening symptoms in weeks 1-3 indicates bacterial die-off and is expected. Manage with:

Activated charcoal 500 mg taken 2+ hours away from all herbs (charcoal absorbs everything indiscriminately)
Increase water to 4+ liters/day
Temporarily halve herb doses for 2-3 days, then resume full dose
Do not stop entirely unless symptoms are severe — stopping removes antimicrobial pressure and allows surviving bacteria to repopulate

Stop and seek medical help if: fever above 103 F / 39.4 C, difficulty breathing, severe chest pain, or symptoms worsen continuously beyond Week 3 with no improvement.

Relevance to Eurasian Species

Most botanical research (Feng et al.) was conducted against B. burgdorferi sensu stricto (North American species). The Goc et al. studies (2015, 2016) are among the few that specifically tested against B. garinii. Chinese skullcap (baicalein) is the strongest Eurasian-specific choice because it was tested directly against B. garinii across all morphological forms. Whether the complete eradication result for cryptolepis against B. burgdorferi replicates against Eurasian species remains an open question — but the Borrelia genus shares core biology, and cryptolepis has broad-spectrum antimicrobial activity.

Important Limitations

All supporting research is in vitro (laboratory). No human clinical trials have been published for this protocol or any of these herbs as Borrelia treatments.
NAC evidence against Borrelia biofilms specifically is extrapolated from its documented activity against biofilms of other bacterial species.
This protocol does not replace conventional antibiotic treatment for confirmed acute Lyme disease or neuroborreliosis.
Individual responses vary. What works in a test tube may not work identically in the body.